Dyne Therapeutics (NASDAQ:DYN) CEO Sells 5,658 Shares

Key Points

• CEO John Cox sold 5,658 Dyne Therapeutics shares at an average price of $18.88, generating $106,823. The sale covered tax withholding obligations, leaving him with 357,507 shares.
• Dyne shares fell 16.4% to $20.31 during Tuesday trading on unusually heavy volume. The company also reported a quarterly loss of $1.08 per share, missing the $0.75 consensus estimate.
• Despite the recent decline, analysts maintain a Moderate Buy consensus with an average price target of $34.17, while institutional investors own 96.68% of the company.

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) CEO John Cox sold 5,658 shares of the business's stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total transaction of $106,823.04. Following the completion of the transaction, the chief executive officer directly owned 357,507 shares of the company's stock, valued at $6,749,732.16. This trade represents a 1.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dyne Therapeutics Trading Down 16.4%

Shares of DYN traded down $3.97 during trading hours on Tuesday, reaching $20.31. The stock had a trading volume of 17,066,387 shares, compared to its average volume of 2,151,348. The company has a market cap of $3.79 billion, a P/E ratio of -6.10 and a beta of 1.08. Dyne Therapeutics, Inc. has a 52 week low of $11.92 and a 52 week high of $27.31. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28. The firm has a 50-day moving average of $24.86 and a 200 day moving average of $20.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.33). On average, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Raymond James Financial restated a "strong-buy" rating and set a $37.00 price objective on shares of Dyne Therapeutics in a report on Tuesday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Dyne Therapeutics in a report on Friday, July 17th. Royal Bank Of Canada lifted their price target on Dyne Therapeutics from $30.00 to $35.00 and gave the company an "outperform" rating in a research note on Thursday, July 30th. HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Dyne Therapeutics in a report on Monday, August 17th. Finally, Morgan Stanley reduced their price objective on Dyne Therapeutics from $47.00 to $45.00 and set an "overweight" rating for the company in a research report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $34.17.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in DYN. T. Rowe Price Investment Management Inc. increased its holdings in shares of Dyne Therapeutics by 523.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company's stock worth $343,085,000 after purchasing an additional 14,727,667 shares during the period. BlackRock Inc. bought a new stake in shares of Dyne Therapeutics during the second quarter worth $275,500,000. Jupiter Topco LLC bought a new stake in Dyne Therapeutics during the 2nd quarter worth $266,634,000. Orbis Allan Gray Ltd acquired a new position in shares of Dyne Therapeutics in the fourth quarter valued at approximately $93,926,000. Finally, Adage Capital Partners GP L.L.C. bought a new position in shares of Dyne Therapeutics during the second quarter valued at $30,378,000. Institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.